-Phase 2 AML Study to Begin by Year End-
Report is Available for Download at: www.lifesciadvisors.com/clients/innate
Innate Pharma (Euronext: IPH) is a leading company in the innate immunology space that just announced positive Phase 1 results for IPH21, the Company’s lead candidate partnered with Bristol-Myers Squibb (NYSE: BMY). The study showed that there was a clear relationship between IPH21 dose, blood concentration, and KIR receptor occupancy. These results support the soon-to-be initiated Phase 2 AML study with IPH21 in elderly AML patients in complete remission.
The aim of the Phase 1 trial was to evaluate the safety, tolerability, and pharmacological profile of IPH21 in elderly AML patients in complete remission after induction and consolidation treatment. The trial has a dose-escalation protocol with seven dose levels ranging from 0.0003 to 3 mg/kg with 3 patients per dose level. Each patient was administered a single dose. The study objective was to determine a safe and pharmacologically active dose. 23 patients were enrolled into the study with a median age of 71.